Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.76 |
| ▸ | LMNA | P02545 | 2/20 | 0.76 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30892454 | 0.96 | HPGD (0.70) | HPGDLMNASMPD1HDAC1HDAC8 | |
| SCHEMBL30892445 | 0.93 | HPGD (0.84) | HPGDLMNASMPD1HDAC1HDAC8 | |
| SCHEMBL24983425 | 0.93 | HPGD (0.84) | HPGDLMNASMPD1HDAC1HDAC8 | |
| SCHEMBL5240840 | 0.93 | HPGD (0.74) | HPGDLMNASMPD1HDAC1HDAC8 | |
| SCHEMBL15369546 | 0.92 | LMNA (0.68) | HPGDLMNASMPD1HDAC1HDAC8 | |
| SCHEMBL30892467 | 0.91 | HPGD (0.64) | HPGDLMNASMPD1HDAC1HDAC8 | |
| SCHEMBL24984300 | 0.91 | HPGD (0.64) | HPGDLMNASMPD1HDAC1HDAC8 | |
| SCHEMBL6664749 | 0.90 | LMNA (0.63) | HPGDLMNASMPD1HDAC1HDAC8 | |
| SCHEMBL24983371 | 0.90 | HPGD (0.67) | HPGDLMNASMPD1HDAC1HDAC8 | |
| SCHEMBL30892464 | 0.90 | HPGD (0.67) | HPGDLMNASMPD1HDAC1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113402417-A | Zinc-aluminum ion recognition fluorescent probe and preparation method and application thereof | 上海交通大学医学院附属瑞金医院 | 2021-09-17 | — | — | CN | claimed |
| US-20240336588-A1 | COMPOSITIONS AND METHODS FOR ANTIOXIDANT AND ANTI-INFLAMMATORY THERAPEUTICS | AVANTI BIOSCIENCES, INC. | 2024-10-10 | — | — | US | disclosed |
| CN-118076589-A | Amide compound, preparation method and pharmaceutical application thereof | 中国科学院上海药物研究所 | 2024-05-24 | — | — | CN | disclosed |
| EP-4370113-A1 | COMPOSITIONS AND METHODS FOR ANTIOXIDANT AND ANTI-INFLAMMATORY THERAPEUTICS | Avanti Biosciences Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| US-11643405-B2 | Compound for treatment or prevention of liver diseases | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2023-05-09 | — | — | US | disclosed |
| US-11643405-B2 | Compound for treatment or prevention of liver diseases | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2023-05-09 | — | — | US | disclosed |
| CN-110183431-B | Compound for treating or preventing liver diseases | 江苏新元素医药科技有限公司 | 2023-04-11 | — | — | CN | disclosed |
| WO-2023288020-A1 | COMPOSITIONS AND METHODS FOR ANTIOXIDANT AND ANTI-INFLAMMATORY THERAPEUTICS | AVANTI BIOSCIENCES INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| WO-2023288020-A1 | COMPOSITIONS AND METHODS FOR ANTIOXIDANT AND ANTI-INFLAMMATORY THERAPEUTICS | AVANTI BIOSCIENCES INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| CN-113402417-B | Zinc-aluminum ion recognition fluorescent probe and preparation method and application thereof | 上海交通大学医学院附属瑞金医院 | 2023-01-03 | — | — | CN | disclosed |
| EP-1265483-B1 | USE OF PHENYLETHYLAMINE DERIVATIVES FOR THE ANITMICROBIAL TREATMENT OF SURFACES | CIBA SC HOLDING AG (CH) | 2006-03-29 | — | — | EP | disclosed |
| US-20060058243-A1 | Methods and compositions for treating diabetes mellitis | OHIO UNIVERSITY | 2006-03-16 | — | — | US | disclosed |
| EP-1545554-A1 | METHODS AND COMPOSITIONS FOR TREATING DIABETES MELLITIS | Ohio University (US) | 2005-06-29 | — | — | EP | disclosed |
| US-6846492-B2 | Use of phenylethylamine derivatives for the antimicrobial treatment of surfaces | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2005-01-25 | — | — | US | disclosed |
| WO-2004009094-A1 | METHODS AND COMPOSITIONS FOR TREATING DIABETES MELLITIS | OHIO UNIVERSITY (US) | 2004-01-29 | — | — | WO | disclosed |
| US-20030207884-A1 | Use of phenylethylamine derivatives for the antimicrobial treatment of surfaces | CIBA SPECIALTY CHEMICALS CORP. | 2003-11-06 | — | — | US | disclosed |
| EP-1265483-A2 | USE OF PHENYLETHYLAMINE DERIVATIVES FOR THE ANITMICROBIAL TREATMENT OF SURFACES | Ciba SC Holding AG (CH) | 2002-12-18 | — | — | EP | disclosed |
| EP-1232169-A1 | GALLOTANNINS AND ELLAGITANNINS AS REGULATORS OF CYTOKINE RELEASE | THE PENN STATE RESEARCH FOUNDATION (US) | 2002-08-21 | — | — | EP | disclosed |
| WO-2001062082-A2 | USE OF PHENYLETHYLAMINE DERIVATIVES FOR THE ANITMICROBIAL TREATMENT OF SURFACES | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2001-08-30 | — | — | WO | disclosed |
| WO-2001036436-A1 | GALLOTANNINS AND ELLAGITANNINS AS REGULATORS OF CYTOKINE RELEASE | THE PENN STATE RESEARCH FOUNDATION (US) | 2001-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058243-A1 | Methods and compositions for treating diabetes mellitis | IAPP, GCG, MTPN | HPGD 2239/4885LMNA 3847/4885SMPD1 855/4885 |
| US-20240336588-A1 | COMPOSITIONS AND METHODS FOR ANTIOXIDANT AND ANTI-INFLAMMATORY THERAPEUTICS | MPO, GPX4, GPX1 | HPGD 147/4885LMNA 1434/4885SMPD1 2570/4885 |
| US-20030207884-A1 | Use of phenylethylamine derivatives for the antimicrobial treatment of surfaces | CLTC, TUBA3C, AOC1 | HPGD 4218/4885LMNA 1106/4885SMPD1 1820/4885 |
| US-11643405-B2 | Compound for treatment or prevention of liver diseases | SLC10A1, GYS2, CPT1A | HPGD 254/4885LMNA 995/4885SMPD1 1078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.